Résumé :
|
[BDSP. Notice produite par INIST-CNRS s7m9R0xt. Diffusion soumise à autorisation]. The authors conducted a nested case-control study of serum inflammatory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n=676) was defined as treatment, report of 2 International Prostate Symptom Score (IPSS) values>14, or 2 increases of>=5 from baseline values with at least one value>=12. Controls (n=683) were men who reported no BPH treatment or IPSS values>7 over the 7-year trial. Baseline serum was analyzed for C-reactive protein, tumor necrosis factor alpha (monomer), soluble tumor necrosis factor receptors I and II (sTNF-RI and sTNF-RII), interleukin 6, and interferon gamma. Controlled for age and race, a high C-reactive protein concentration was associated with increased BPH risk (for quartile 4 vs. quartile 1, odds ratio (OR)=1.40,95% confidence interval (CI) : 1.04,1.88) ; this was attenuated after control for body mass index (OR=1.30,95% CI : 0.95,1.75). Low sTNF-RII and high interleukin 6 concentrations were associated with increased BPH risk (for quartile 4 vs. quartile 1, sTNF-RII : OR=0.61,95% CI : 0.46,0.82 ; interleukin 6 : OR=1.79,95% CI : 1.32,2.42) ; these associations were only in men aged<65 years. Results suggest that systemic inflammation or lower levels of soluble receptors that bind inflammatory cytokines increase BPH risk.
|